Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Alkylating Drug [EPC]
Busulfan is a potent bifunctional alkylating agent used primarily for the treatment of chronic myeloid leukemia and as a conditioning regimen before bone marrow transplantation. It works by interfering with DNA replication to inhibit cancer cell growth.
Name
Busulfan
Raw Name
BUSULFAN
Category
Alkylating Drug [EPC]
Drug Count
4
Variant Count
13
Last Verified
February 17, 2026
RxCUI
253113, 105551, 197422, 284425
UNII
G1LN9045DK
About Busulfan
Busulfan is a potent bifunctional alkylating agent used primarily for the treatment of chronic myeloid leukemia and as a conditioning regimen before bone marrow transplantation. It works by interfering with DNA replication to inhibit cancer cell growth.
Detailed information about Busulfan
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Busulfan.
Busulfan is a potent, cell-cycle non-specific bifunctional alkylating agent (a type of chemotherapy that damages the DNA of cancer cells) belonging to the group of methanesulfonates. Originally approved by the U.S. Food and Drug Administration (FDA) in 1954 under the brand name Myleran, it has remained a cornerstone in the management of certain hematologic malignancies (blood cancers). Busulfan is classified pharmacologically as an Alkylating Drug [EPC]. In clinical practice, it is primarily utilized in two distinct settings: the palliative treatment of chronic myeloid leukemia (CML) and as a high-dose conditioning agent prior to hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation.
Unlike many other chemotherapy drugs that are derived from natural sources, busulfan is a synthetic compound. It is designed to target rapidly dividing cells, which is why it is effective against cancer but also why it affects healthy tissues like the bone marrow, hair follicles, and the lining of the digestive tract. Over the decades, the delivery of busulfan has evolved significantly. While it was initially available only as an oral tablet, the development of intravenous (IV) formulations (such as Busulfex) in the late 1990s revolutionized its use in transplant medicine, allowing for more predictable blood levels and reduced gastrointestinal toxicity. Your healthcare provider will determine which formulation is appropriate based on your specific diagnosis and treatment goals.
At the molecular level, busulfan functions through a process called alkylation. It is a bifunctional agent, meaning it has two reactive groups that can bind to DNA. Specifically, busulfan reacts with the N7 position of guanine residues (building blocks of DNA). Because it has two reactive sites, it can form 'cross-links' between two different DNA strands or within the same strand. These cross-links act like physical 'staples' that prevent the DNA double helix from unzipping.
When a cell attempts to replicate its DNA to divide, the presence of these cross-links causes the replication machinery to stall. This leads to DNA strand breaks and triggers a process called apoptosis (programmed cell death). Because cancer cells, particularly those in the bone marrow of CML patients, divide much faster than most normal cells, they are disproportionately affected by this mechanism. In the context of bone marrow transplantation, high doses of busulfan are used to 'clear out' or ablate the patient's existing diseased bone marrow to make room for healthy donor cells. This process is known as myeloablation. It is important to understand that busulfan does not distinguish between healthy and cancerous blood-forming cells, which is why close medical supervision is required during treatment.
Understanding how the body processes busulfan is critical for safety, especially since the drug has a narrow therapeutic index (a small margin between an effective dose and a toxic dose).
Busulfan is FDA-approved for the following indications:
Off-label uses, which are uses not specifically approved by the FDA but supported by clinical evidence, include conditioning for other types of leukemia, lymphomas, and certain non-malignant disorders like sickle cell anemia or thalassaemia when a transplant is required.
Busulfan is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Busulfan is right for your specific condition. The choice of formulation and dosage is a complex medical decision based on your diagnosis, body weight, and overall health status.
Dosage for busulfan is highly individualized and depends on the specific condition being treated and the patient's body surface area or weight.
Busulfan is frequently used in pediatric patients undergoing stem cell transplantation. However, children often clear busulfan from their systems much faster than adults, requiring higher weight-based doses.
Specific guidelines for renal (kidney) impairment are not well-established because busulfan is primarily cleared by the liver. However, since metabolites are excreted renally, healthcare providers exercise caution in patients with severe kidney disease. No specific starting dose adjustment is usually required, but close monitoring of toxicity is essential.
Busulfan is heavily metabolized by the liver. Patients with pre-existing liver disease or hepatic impairment are at a significantly increased risk of developing Sinusoidal Obstruction Syndrome (SOS), formerly known as Veno-Occlusive Disease (VOD). Dose reductions may be considered, and these patients are monitored with extreme frequency for signs of liver stress.
Clinical studies have not identified significant differences in response between elderly and younger patients. However, because older adults are more likely to have decreased renal or hepatic function, doctors typically start at the lower end of the dosing range and monitor blood counts closely.
If you miss a dose of oral busulfan, contact your healthcare provider immediately. Do not 'double up' on the next dose to catch up. Because busulfan significantly affects your bone marrow, timing is critical, and your doctor will need to decide the best course of action based on how long it has been since the missed dose.
An overdose of busulfan is a medical emergency. The primary sign of overdose is profound myelosuppression (a severe drop in white blood cells, red blood cells, and platelets), which may not appear for several days. Other signs include seizures, nausea, and vomiting. There is no specific antidote for busulfan. Treatment focuses on supportive care, including blood transfusions, growth factors to stimulate white blood cell production, and anti-seizure medications. If an oral overdose is suspected, seek emergency medical attention or call a poison control center immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without direct medical guidance, as this can lead to treatment failure or severe complications.
Busulfan is a powerful chemotherapy drug, and side effects are expected, especially at high doses used for transplant.
> Warning: Stop taking Busulfan and call your doctor immediately if you experience any of these serious symptoms.
Busulfan carries a significant FDA Black Box Warning regarding Bone Marrow Suppression. The drug causes severe and prolonged myelosuppression. At the doses used for transplant conditioning, it is intended to cause 'pancytopenia' (a total lack of all blood cell types). This state is life-threatening unless the patient receives a rescue of stem cells (a transplant). Patients must be monitored in a facility capable of providing intensive supportive care, including blood products and potent antibiotics. Another warning often associated with high-dose use is the risk of Seizures, which requires prophylactic (preventative) treatment with anticonvulsants.
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular blood monitoring is the only way to safely manage these risks.
Busulfan is a high-alert medication that must only be administered under the supervision of a physician experienced in cancer chemotherapy and bone marrow transplantation. The most critical safety concern is the drug's ability to profoundly suppress the bone marrow, which can lead to fatal infections or bleeding if not managed in a specialized hospital setting.
Severe Myelosuppression: Busulfan can cause severe, prolonged, and potentially irreversible bone marrow failure. This results in a dangerous decrease in white blood cells, red blood cells, and platelets. Frequent monitoring of complete blood counts (CBC) is mandatory. At high doses used for transplant, this effect is intentional but requires the subsequent infusion of stem cells to restore blood production.
During treatment, you will require frequent testing to ensure the drug is working and to catch side effects early:
Busulfan may cause dizziness or increase the risk of seizures. You should not drive or operate heavy machinery until you know how the medication affects you and until your doctor confirms that the risk of treatment-induced seizures has passed.
Alcohol should be avoided during busulfan treatment. Alcohol can strain the liver, which is already working hard to process the chemotherapy, and may increase the risk of liver-related side effects like SOS. Furthermore, alcohol can lower the seizure threshold, increasing the danger of neurological complications.
In the treatment of CML, busulfan is not typically 'tapered,' but it must be stopped immediately if blood counts fall below a certain safety threshold. In the transplant setting, the drug is given as a short, intense course. Never stop taking oral busulfan without consulting your oncologist, as this can lead to a rapid increase in your white blood cell count and a worsening of your leukemia.
> Important: Discuss all your medical conditions, especially any history of liver disease, lung disease, or seizures, with your healthcare provider before starting Busulfan.
Certain drugs should never be used with busulfan because they significantly increase the risk of fatal toxicity.
Busulfan does not typically interfere with the chemical process of lab tests, but its biological effects will profoundly change lab results, including:
For each major interaction, the mechanism usually involves the depletion of glutathione or the induction/inhibition of metabolic pathways. The clinical consequence is either increased toxicity (liver failure, seizures) or reduced efficacy (cancer relapse).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers like Tylenol.
Conditions where Busulfan must NEVER be used include:
Conditions requiring careful risk-benefit analysis include:
There is a potential for cross-sensitivity between busulfan and other alkylating agents (like treosulfan). If you have had a reaction to other 'sulfonate' type drugs, inform your doctor immediately.
> Important: Your healthcare provider will evaluate your complete medical history, including all past allergies and prior treatments, before prescribing Busulfan.
Busulfan is classified as a pregnancy hazard (formerly FDA Category D). There is clear evidence of human fetal risk based on adverse reaction data from investigational or marketing experience. Busulfan is 'teratogenic,' meaning it can cause physical defects in the developing fetus, including musculoskeletal abnormalities and stunted growth. It can also cause 'pancytopenia' (low blood counts) in the newborn. Women of childbearing potential must use highly effective contraception during treatment. If pregnancy occurs while taking busulfan, the patient must be apprised of the potential hazard to the fetus.
It is not known whether busulfan is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (including cancer and immune suppression), breastfeeding is strictly contraindicated during busulfan therapy. Most protocols recommend waiting several weeks after the final dose before considering breastfeeding, but this must be discussed with a doctor.
Busulfan is a standard component of conditioning regimens for children undergoing bone marrow transplants for leukemia or genetic blood disorders. However, pediatric use requires specialized expertise. Children under the age of 13 often have a higher clearance rate for busulfan, meaning they may need more frequent or higher doses than adults to achieve the same therapeutic effect. Conversely, infants may be at higher risk for toxicity. Pediatric dosing should always be guided by therapeutic drug monitoring (TDM) to ensure the 'Area Under the Curve' (AUC) is within the safe and effective range.
Clinical studies of busulfan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
While the kidneys are not the primary route of busulfan metabolism, the drug's metabolites are excreted in the urine. In patients with a Glomerular Filtration Rate (GFR) of less than 30 mL/min, there is a theoretical risk of metabolite accumulation. However, standard practice typically does not require a starting dose adjustment for mild-to-moderate renal impairment, though hydration must be carefully managed to prevent kidney stones from cell breakdown.
Patients with pre-existing hepatic impairment (e.g., Child-Pugh Class B or C) are at a significantly higher risk for Sinusoidal Obstruction Syndrome (SOS). Busulfan clearance is reduced in these patients. If busulfan must be used, a dose reduction is often necessary, and the patient should be monitored daily for weight gain, jaundice, and liver pain. The use of prophylactic medications like ursodiol may be considered to protect the liver.
> Important: Special populations require individualized medical assessment and often require more frequent lab monitoring and dose adjustments.
Busulfan is a bifunctional alkylating agent of the methanesulfonate class. Its chemical structure (1,4-butanediol dimethanesulfonate) allows it to undergo nucleophilic substitution reactions. In the body, the methanesulfonate groups leave, creating reactive carbonium ions. these ions then form covalent bonds with the DNA bases, specifically the N7 position of guanine. Because busulfan has two such reactive groups, it can create interstrand cross-links. These cross-links are particularly difficult for cells to repair. The resulting DNA damage prevents the cell from progressing through the cell cycle (specifically inhibiting the S-phase and G2-phase), eventually leading to cell death. This effect is not specific to any one phase of the cell cycle, though it is most lethal to cells that are actively dividing.
Busulfan shows a clear dose-response relationship regarding bone marrow suppression. At low doses, it selectively suppresses granulocytes (a type of white blood cell), which makes it useful for CML. At high doses, it causes 'pan-myeloablation,' destroying all hematopoietic stem cells. The onset of the lowest blood count (nadir) typically occurs 10 to 14 days after administration, but with busulfan, the recovery can be much slower than with other chemotherapy drugs, sometimes taking several weeks.
| Parameter | Value |
|---|---|
| Bioavailability | Oral: 70-80% (highly variable); IV: 100% |
| Protein Binding | 7% to 32% (primarily albumin) |
| Half-life | 2.5 to 3 hours (Adults); shorter in children |
| Tmax | 0.9 to 2 hours (Oral) |
| Metabolism | Hepatic (Glutathione conjugation via GST) |
| Excretion | Renal (approx. 30% as metabolites within 48 hours) |
Busulfan belongs to the therapeutic class of Antineoplastic Agents and the pharmacologic class of Alkylating Drugs. It is chemically distinct from nitrogen mustards (like cyclophosphamide) or nitrosoureas (like carmustine), as it is a bifunctional alkyl ester of methanesulfonic acid. Related medications include Treosulfan, which is also used in transplant conditioning.
Common questions about Busulfan
Busulfan is primarily used for two medical purposes: the palliative treatment of chronic myeloid leukemia (CML) and as a conditioning agent before a bone marrow or stem cell transplant. In CML, it helps control the overproduction of white blood cells, although it is not a cure. In the transplant setting, high doses are used to intentionally destroy the patient's existing diseased bone marrow to make room for healthy donor cells. This process is essential for the success of the transplant. It may also be used off-label for other blood disorders like polycythemia vera or certain types of lymphoma.
The most common side effects include a significant drop in blood cell counts (anemia, increased risk of infection, and easy bleeding), nausea, vomiting, and mouth sores. Many patients also experience a darkening of the skin, often called a 'busulfan tan,' which is usually harmless. At the high doses used for transplants, side effects are more severe and can include hair loss, diarrhea, and profound fatigue. Because it affects the liver, some patients may also experience jaundice or abdominal swelling. Close monitoring by a medical team is required to manage these effects.
No, you should strictly avoid alcohol while being treated with busulfan. Alcohol is processed by the liver and can increase the strain on this organ, which is already working to metabolize the chemotherapy. This increases the risk of serious liver complications like Sinusoidal Obstruction Syndrome (SOS). Additionally, busulfan carries a risk of causing seizures, and alcohol consumption can further lower the seizure threshold, making a neurological event more likely. Always check with your oncologist before consuming any alcohol during or shortly after your treatment course.
Busulfan is not considered safe during pregnancy and is known to cause birth defects and fetal death. It is an alkylating agent that damages DNA, which can severely interfere with the development of a fetus. Women of childbearing age must use effective birth control while taking this medication. If you become pregnant while taking busulfan, you must notify your doctor immediately to discuss the risks. Furthermore, busulfan can cause permanent infertility in both men and women, so fertility preservation should be discussed before starting therapy.
The time it takes for busulfan to work depends on the condition being treated. In chronic myeloid leukemia, you may see a decrease in your white blood cell count within 1 to 2 weeks of starting the oral tablets. In the transplant setting, the drug works rapidly to clear the bone marrow over the 4-day administration period, though the full 'nadir' (the point of lowest blood counts) usually occurs about 7 to 14 days after the first dose. Your doctor will use frequent blood tests to track the drug's effectiveness and your body's response.
You should never stop taking busulfan suddenly without your doctor's explicit instructions. In the treatment of CML, stopping the medication abruptly can cause your white blood cell count to rise rapidly, which can lead to a worsening of your condition or a 'blast crisis.' In a transplant setting, the timing of busulfan is precisely coordinated with other medications and the infusion of stem cells; any interruption can cause the transplant to fail. If you are experiencing side effects that make it difficult to take the medicine, contact your oncology team immediately for guidance.
If you miss a dose of oral busulfan, call your doctor or pharmacist right away for instructions. Do not take a double dose to make up for the one you missed, as this can lead to dangerous toxicity. Because busulfan has a narrow therapeutic window, the timing of each dose is very important for maintaining the correct level of the drug in your blood. Your healthcare provider will advise you on whether to take the dose late or skip it based on how much time has passed. Keep a record of any missed doses to show your medical team.
Busulfan itself does not typically cause fat-based weight gain, but it can cause rapid weight gain due to fluid retention. This is a potentially serious sign of liver toxicity known as Sinusoidal Obstruction Syndrome (SOS). If you notice sudden swelling in your abdomen, puffiness in your legs, or a weight increase of several pounds in a single day, you must report it to your doctor immediately. While some patients may lose weight due to nausea and loss of appetite, any rapid increase in weight during busulfan therapy is treated as a medical concern until fluid retention is ruled out.
Busulfan has several significant drug interactions, so it must be used with caution alongside other medications. Most notably, it interacts with acetaminophen (Tylenol), which can increase the risk of liver damage. It also interacts with certain antibiotics like metronidazole and antifungals like itraconazole, which can raise busulfan levels to toxic heights. Conversely, some anti-seizure drugs like phenytoin can lower busulfan levels, potentially making the treatment less effective. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking.
Yes, busulfan is available as a generic medication in both its oral tablet form and its intravenous injection form. The generic versions are required by the FDA to have the same active ingredient, strength, and effectiveness as the brand-name versions (Myleran and Busulfex). Using generic busulfan can often reduce the cost of treatment. However, because this is a complex chemotherapy drug, your hospital's pharmacy will typically manage the specific brand or generic version used during your stay. Discuss any cost concerns with your hospital's financial counselor or your oncology team.